Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML9AVG)

Drug Name

IMG-7289 Drug Info

Synonyms

KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Phase 2	[1]
Myelodysplastic syndrome	2A37	Phase 2	[1]
Myelofibrosis	2A20.2	Phase 1/2	[1]

Cross-matching ID

PubChem CID: 122460381
CAS Number: CAS 1990504-34-1
TTD Drug ID: DML9AVG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Lysine-specific histone demethylase 1 (LSD)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[1]
CC-90011	DM0EDHJ	Lymphoma	2A80-2A86	Phase 2	[2]
Vafidemstat	DM64ZGY	Alzheimer disease	8A20	Phase 2	[3]
ORY-2001	DMYM0UY	Alzheimer disease	8A20	Phase 2	[4]
INCB59872	DMRLV7G	Acute myeloid leukaemia	2A60	Phase 1/2	[1]
GSK2879552	DMT3V2W	Small-cell lung cancer	2C25.Y	Phase 1	[5]
Seclidemstat	DMCP7SD	Ewing sarcoma	2B52	Phase 1	[6]
TAS-1440	DMHIA7Y	Acute myeloid leukaemia	2A60	Phase 1	[7]
Tarnylcypromine derivative 2	DMEJR2F	N. A.	N. A.	Patented	[8]
Tarnylcypromine derivative 3	DMKJOMC	N. A.	N. A.	Patented	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Lysine-specific histone demethylase 1 (LSD)	TTNR0UQ	KDM1A_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
3	Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
4	Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
5	A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
6	Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
7	Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
8	LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.